ABSTRACT
Objective: To evaluate the relationship between ABO blood group system and the risk of gastric cancer by case-control study and meta-analysis. Methods: In our case-control study, 930 cases of gastric cancer were enrolled and 8 426 cases with other diseases were taken as controls from Changhai Hospital. PubMed were searched with unlimited initial time and the cutoff time on December 31, 2013; and our case-control study was also included. Two reviewers evaluated the quality of the included case-control studies by Newcastle-Ottawa scale (NOS) and extracted the data independently. The meta-analysis was performed by Meta-Analyst 3. 13 software. Results: The case-control study showed that blood type A might be a risk factor of gastric cancer (0R=1. 58;95%CI: 1. 37-1. 81). The results of meta-analysis showed that the risk of gastric cancer of blood group A was signiticantly higher than that of non-A groups (0R=1. 28; 95%CI: 1. 01-1. 62); meanwhile, blood group O demonstrated a lower risk of gastric cancer compared with non-O groups (OR=0. 84;95%CI: 0. 73-0. 96); subgroup analysis found differences between home population and foreign population. Conclusion: ABO blood group system is associated with the risk of gastric cancer, and type A might be one of the risk factors of gastric cancer.
ABSTRACT
Despite chemotherapy regimens foradvanced gastric cancer keep emerging, the patients stillhave poor prognosis. Molecular targeted therapy is another important direction for the treatment of advanced gastric cancer. Various drugs for molecular targeted therapy have been developed targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2), vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and cyclooxygenase-2 (COX-2); a number of II /W clinical trial have been completed or being conducted. The aim of this review is to summarize the recent progress on molecular targeted therapy for gastric cancer.